| |  | This week in First Opinion, authors explored: An underground market for affordable insulin. Paying up to make academic medicine a more diverse undertaking. Lessons learned from previous biotech stock "dumpster fires." A language of healing that doesn't require the word cure. And more. You can read them all here. | | | | By Alina Bills Adobe Some people with diabetes must turn to an underground market for affordable insulin and other supplies. They shouldn't have to do that. Read More | | By Joshua A. Budhu Adobe One way to solve the diversity gap in academic medicine is for institutions to increase compensation across the board. Read More | | By Edward M. Kaye Hyacinth Empinado/STAT Even when headline writers are using their grimmest language about biotech stocks, innovation eventually wins — and so do patients. Read More | | Sponsor content by STAT+ Biopharma breakthroughs, business, and policy analysis — at your fingertips Enjoy daily, market-moving analysis of the biotech, pharma, and life sciences industries with STAT Plus. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Don't be the last to know. Subscribe today to start reading. | | By Lee D. Cooper Adobe Stopping a genetic disease in its tracks, and maybe even reversing its progression, is an extraordinary achievement. But it is seldom a cure. Read More | | By Bruce Farber and Aradhana Khameraj JOSEPH PREZIOSO/AFP via Getty Images Outdated guidelines on health care workers' use of personal protective equipment are contributing to a huge waste disposal problem. Read More | | By Neil Dhawan Adobe Advances in computation, chemistry, and biology are paving the way to developing small molecule drugs with advanced capabilities. Read More | | By John J. Doyle and Anam M. Khan and Jowanna R. Malone Adobe Biopharma companies must play a leading role in reducing inequities so more people can access digital health tools. Read More | | By Gary Michelson and Aysha Akhtar Adobe The 1938 Federal Food, Drug, and Cosmetic Act, which requires that every drug be tested on animals, needs a 21st century update. Read More | | By Mark Reisenauer Adobe Using Bayh-Dole march-in rights to lower a drug's price would set a troubling precedent and jeopardize new drug discovery and development. Read More | |
No comments